Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.

Pharmacogenomics - 1 Dec 2011

Zineh Issam, Mummaneni Padmaja, Lyndly Jenna, Amur Shashi, La Grenade Lois A, Chang Stephen H, Rogers Hobart, Pacanowski Michael A

Abstract excerpt

Use of pharmacogenetics to inform treatment decisions remains a priority for clinicians, patients and public health agencies. We previously developed a framework for systematically assessing whether pharmacogenetic test information would likely bring value to clinical decision-making and enjoy practical uptake. We applied this tool to allopurinol to determine potential usefulness of HLA genetic information in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Gout
Share to Gout Suppressants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA Antigens

Share to Hyperuricemia

Share to Pharmacogenetics

Share to Skin Diseases

Share to Stevens-Johnson Syndrome

Source

Identifiers

PMID: 22118056
DOI: 10.2217/pgs.11.131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allopurinol pharmacogenetics: assessment of potential clinical usefulness.PMID 22118056Read ↗

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Semantic proximity Read ↗

Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Semantic proximity Read ↗

Genotyping HLA alleles to predict the development of Severe cutaneous adverse drug reactions (SCARs): state-of-the-art.Semantic proximity Read ↗

Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation.Semantic proximity Read ↗

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Semantic proximity Read ↗

Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity.Semantic proximity Read ↗

Pharmacogenetic markers of severe cutaneous adverse drug reactions.Semantic proximity Read ↗

Pharmacogenetics of cutaneous adverse drug reactionsSemantic proximity Read ↗

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationSemantic proximity Read ↗

HLA-B*58:01 is an Incomplete Predictor of Allopurinol-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.